Safety and non-inferiority of multidose and single-dose vial formulations of EuTCV Vi-CRM197 versus Typbar TCV in healthy participants in Kenya and Senegal: a multicentre, observer-blind, randomised, phase 3 study.
Saved in:
| Title: | Safety and non-inferiority of multidose and single-dose vial formulations of EuTCV Vi-CRM197 versus Typbar TCV in healthy participants in Kenya and Senegal: a multicentre, observer-blind, randomised, phase 3 study. |
|---|---|
| Authors: | Ndiaye BP; Institute for Health Research - Epidemiological Surveillance and Training, Dakar, Senegal., Koech L; Kenya Medical Research Institute-US Army Medical Research Directorate Africa-HJF Medical Research International, Kericho, Kenya., Mercer LD; PATH Center for Vaccine Innovation and Access, Seattle, WA, USA., Aponte JJ; PATH Center for Vaccine Innovation and Access, Geneva, Switzerland., Cisse B; Institute for Health Research - Epidemiological Surveillance and Training, Dakar, Senegal., Riziki F; Kenya Medical Research Institute-US Army Medical Research Directorate Africa-HJF Medical Research International, Kericho, Kenya., Keter W; Kenya Medical Research Institute-US Army Medical Research Directorate Africa-HJF Medical Research International, Kericho, Kenya., Eaton N; PATH Center for Vaccine Innovation and Access, Seattle, WA, USA., Diye S; Institute for Health Research - Epidemiological Surveillance and Training, Dakar, Senegal., Wade D; Institute for Health Research - Epidemiological Surveillance and Training, Dakar, Senegal., Bob NS; Institut Pasteur de Dakar, Dakar, Senegal., Raine MG; PATH Center for Vaccine Innovation and Access, Seattle, WA, USA., Her H; EuBiologics, Seoul, South Korea., Kim S; EuBiologics, Seoul, South Korea., Erdem R; PATH Center for Vaccine Innovation and Access, Seattle, WA, USA., Lee C; EuBiologics, Seoul, South Korea., Cassels FJ; PATH Center for Vaccine Innovation and Access, Seattle, WA, USA., Park Y; EuBiologics, Seoul, South Korea., Dia M; Institut Pasteur de Dakar, Dakar, Senegal., Baik YO; EuBiologics, Seoul, South Korea., Fall G; Institut Pasteur de Dakar, Dakar, Senegal., Locke E; PATH Center for Vaccine Innovation and Access, Seattle, WA, USA., Njuguna PW; PATH Center for Vaccine Innovation and Access, Nairobi, Kenya. Electronic address: pnjuguna@path.org. |
| Source: | The Lancet. Global health [Lancet Glob Health] 2025 Dec; Vol. 13 (12), pp. e2122-e2132. |
| Publication Type: | Journal Article; Multicenter Study; Randomized Controlled Trial; Clinical Trial, Phase III; Equivalence Trial |
| Journal Info: | Publisher: Elsevier Ltd Country of Publication: England NLM ID: 101613665 Publication Model: Print Cited Medium: Internet ISSN: 2214-109X (Electronic) Linking ISSN: 2214109X NLM ISO Abbreviation: Lancet Glob Health Subsets: MEDLINE |
| Database: | MEDLINE Ultimate |
Be the first to leave a comment!
